Karuna Therapeutics

General Information


We are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. Our pipeline is built on the broad therapeutic potential of our lead product candidate, KarXT, an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues. KarXT is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. We are currently conducting a Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia and expect topline results in late 2019.

Employees: 16
Founded: 2009
Contact Information
Address 33 Arch Street, Suite 3110, Boston, MA 02110, US
Phone Number (857) 449-2244
Web Address http://www.karunatx.com
View Prospectus: Karuna Therapeutics
Financial Information
Market Cap $341.9mil
Revenues $0 mil (last 12 months)
Net Income $-27.1 mil (last 12 months)
IPO Profile
Symbol KRTX
Exchange NASDAQ
Shares (millions): 5.6
Price range $16.00 - $16.00
Est. $ Volume $89.2 mil
Manager / Joint Managers Goldman Sachs/ Citigroup/ Wells Fargo Securities
CO-Managers Wedbush Securities
Expected To Trade: 6/28/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change